New Zealand Authorizes MDMA for Treatment of Severe PTSD

New Zealand's drug regulatory agency, Medsafe, has authorized two psychiatrists to prescribe pharmaceutical grade MDMA to treat patients with severe post traumatic stress disorder (PTSD). This decision makes New Zealand the second country in the world to allow the medical use of the substance for this purpose, following Australia's lead in 2023. Deputy Prime Minister David Seymour stated that PTSD destroys lives and is difficult to treat, adding that the country is committed to expanding access to innovative treatments. Seymour previously supported the use of hallucinogenic mushrooms for severe depression.

The Ministry of Health specified that the treatment must be combined with psychotherapy and is restricted to patients over 18 years old. The substance cannot be taken home and must be administered in a controlled clinical setting under the supervision of authorized psychiatrists. PTSD is a mental health disorder that develops after experiencing or being threatened by traumatic events, such as military combat, sexual assault, or natural disasters.

While New Zealand and Australia have moved toward legalization, the United States Food and Drug Administration (FDA) rejected the medicinal legalization of MDMA in 2024, citing insufficient evidence of its safety and efficacy. In the U.S. only two types of antidepressants are currently approved for PTSD treatment, though clinical trials for MDMA continue. Some regions in Canada and certain U.S. states have allowed the use of MDMA and psilocybin exclusively for clinical trials or under special permits.